Trial Profile
A Randomized, Parallel Design Study to Compare the Safety and Effectiveness of Gardasil When Delivered Per Standard Practice (Full Dose, Intramuscular (IM) Delivery Using a Needle and Syringe) vs. Full Dose, IM Delivery Via Needle-free Jet Injection or Reduced Dose, Intradermal Delivery Via Needle-free Jet Injection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2023
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Human papillomavirus infections
- Focus Therapeutic Use
- Acronyms GINI
- 15 Feb 2023 Status changed from active, no longer recruiting to completed.
- 08 Jul 2021 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.
- 08 Jul 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2022.